Physician profile
Inchol Yun
NPI 1740332840
$13,891.43
in general payments reported to CMS, 2019-2025
52 companies · $2,461 in 2025
The $2,461 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,460 · 2020: $1,309 · 2021: $1,803 · 2022: $1,803 · 2023: $2,002 · 2024: $2,054 · 2025: $2,461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,517.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,517.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,766.17 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $1,201.60 | 2019-2025 | |
| Amgen INC. | $1,089.35 | 2019-2025 | Repatha, Otezla, Otezla |
| Astrazeneca Pharmaceuticals LP | $989.61 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $943.35 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $733.25 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Abbvie INC. | $668.27 | 2021-2025 | Ubrelvy, Linzess, Viberzi |
| Supernus Pharmaceuticals, INC. | $620.84 | 2021-2022 | Xyosted |
| Takeda Pharmaceuticals U.S.A., INC. | $442.28 | 2020-2025 | Trintellix |
| Amarin Pharma, INC. | $423.48 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $411.48 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Shield Therapeutics INC | $355.54 | 2023-2025 | Accrufer |
| Glaxosmithkline, LLC. | $353.22 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $318.16 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $264.15 | 2022-2024 | Quviviq |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Inchol Yun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.